Associated Papers
Validation of diagnostic screening test for pharmacogenomic targets for thiopurine drugs in indian pediatric acute lymphoblastic leukemia patients.
Joseph GT et al.
Frontiers in Pharmacology, 2025
Genetic profiling of NUDT15 in the Slovenian population.
Šmid A et al.
Pharmacogenomics, 2024
The Effect of NUDT15, TPMT, APEX1, and ITPA Genetic Variations on Mercaptopurine Treatment of Pediatric Acute Lymphoblastic Leukemia.
Lee JM et al.
Children (basel, Switzerland), 2021
NUDT15 gene variants and thiopurine-induced leukopenia in patients with inflammatory bowel disease.
Matsuoka K
Intestinal Research, 2020
Thiopurine-mediated impairment of hematopoietic stem and leukemia cells in Nudt15R138C knock-in mice.
Tatsumi G et al.
Leukemia, 2020
Pharmacogene Variation Consortium Gene Introduction: NUDT15.
Yang JJ et al.
Clinical Pharmacology and Therapeutics, 2019
30515762 (PubMed )
Supplement: CPT-105-1091-s001.xlsx › NUDT15_nomenclature_
NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study.
Kakuta Y et al.
Journal of Gastroenterology, 2018
Pharmacogenetics of thiopurines for inflammatory bowel disease in East Asia: prospects for clinical application of NUDT15 genotyping.
Kakuta Y et al.
Journal of Gastroenterology, 2018
Select a paper to view details